Human immunodeficiency virus type 1 (HIV-1) virions are released from cells as immature, noninfectious particles that must subsequently undergo proteolytic maturation to become infectious. Entry of virions into new target cells occurs through a membrane fusion reaction mediated by the Env glycoproteins gp120 and gp41. Although the mechanism of Env-catalyzed membrane fusion is relatively well characterized, less clear is the role of the 152 amino acid gp41 cytoplasmic domain in Env-mediated fusion. We have recently discovered that immature HIV-1 particles are inhibited for fusion through a mechanism involving the gp41 cytoplasmic tail (CT). Truncation of the tait_ or cleavage of Pr55Gag between the MA and NC domains, activates HIV-1 particles for fusion. This novel mechanism for regulating fusion may promote HIV-1 replication by enhancing productive entry of the virus, in addition, by inhibiting Env conformationat changes until the core has matured, the gp41-Gag interaction may confer a replicative advantage by limiting exposure of Env epitopes recognized by neutralizing antibodies. We propose here a series of six highly focused Specific Aims to dissect the mechanism of immature HIV-1 fusion inhibition and to determine the consequences to HIV-1 replication. Specifically, we will: 1. Determine whether maturation-dependent HIV-1 fusion extends to R5-tropic Env and Gag proteins from HIV-1 primary isolates; 2. Map the regions of the gp41 CT required for fusion inhibition; 3. Determine the role of lipid rafts in coupling HIV-1 fusion to virion maturation; 4. Quantify receptor-induced conformationat changes on immature HIV-1 particles; 5. Determine the role of viral RNA in fusion inhibition; and 6. Evaluate the role of the gp41 CT in conferring resistance to neutralizing antibodies during continuous HIV-1 replication. These studies will reveal new fundamental insights into the regulation of HIV-t entry and the role of the gp41 cytoplasmic tail in HIV-1 replication.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI047056-08
Application #
7169575
Study Section
Special Emphasis Panel (ZRG1-AARR-1 (02))
Program Officer
Gupta, Kailash C
Project Start
1999-12-01
Project End
2009-12-31
Budget Start
2007-01-01
Budget End
2009-12-31
Support Year
8
Fiscal Year
2007
Total Cost
$322,145
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Joyner, Amanda S; Willis, Jordan R; Crowe Jr, James E et al. (2011) Maturation-induced cloaking of neutralization epitopes on HIV-1 particles. PLoS Pathog 7:e1002234
Pion, Marjorie; Arrighi, Jean-Francois; Jiang, Jiyang et al. (2007) Analysis of HIV-1-X4 fusion with immature dendritic cells identifies a specific restriction that is independent of CXCR4 levels. J Invest Dermatol 127:319-23
Jiang, Jiyang; Aiken, Christopher (2007) Maturation-dependent human immunodeficiency virus type 1 particle fusion requires a carboxyl-terminal region of the gp41 cytoplasmic tail. J Virol 81:9999-10008
Davis, Melody R; Jiang, Jiyang; Zhou, Jing et al. (2006) A mutation in the human immunodeficiency virus type 1 Gag protein destabilizes the interaction of the envelope protein subunits gp120 and gp41. J Virol 80:2405-17
Jiang, Jiyang; Aiken, Christopher (2006) Maturation of the viral core enhances the fusion of HIV-1 particles with primary human T cells and monocyte-derived macrophages. Virology 346:460-8
Wyma, Donald J; Jiang, Jiyang; Shi, Jiong et al. (2004) Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail. J Virol 78:3429-35
Zhou, J; Aiken, C (2001) Nef enhances human immunodeficiency virus type 1 infectivity resulting from intervirion fusion: evidence supporting a role for Nef at the virion envelope. J Virol 75:5851-9
Wyma, D J; Kotov, A; Aiken, C (2000) Evidence for a stable interaction of gp41 with Pr55(Gag) in immature human immunodeficiency virus type 1 particles. J Virol 74:9381-7